These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27770239)

  • 1. Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues.
    Mayo BJ; Stringer AM; Bowen JM; Bateman EH; Keefe DM
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):233-249. PubMed ID: 27770239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptides 1 and 2: intestinal hormones implicated in the pathophysiology of mucositis.
    Kissow H
    Curr Opin Support Palliat Care; 2015 Jun; 9(2):196-202. PubMed ID: 25872118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis.
    Kissow H; Hartmann B; Holst JJ; Poulsen SS
    Gut; 2013 Dec; 62(12):1724-33. PubMed ID: 23086829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
    Ribeiro RA; Wanderley CW; Wong DV; Mota JM; Leite CA; Souza MH; Cunha FQ; Lima-Júnior RC
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):881-893. PubMed ID: 27590709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activation.
    Alvarenga EM; Souza LK; Araújo TS; Nogueira KM; Sousa FB; Araújo AR; Martins CS; Pacífico DM; de C Brito GA; Souza EP; Sousa DP; Medeiros JV
    Chem Biol Interact; 2016 Dec; 260():129-140. PubMed ID: 27838229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
    Boushey RP; Yusta B; Drucker DJ
    Cancer Res; 2001 Jan; 61(2):687-93. PubMed ID: 11212269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a single-dose irinotecan model of gastrointestinal mucositis.
    Gibson RJ; Bowen JM; Alvarez E; Finnie J; Keefe DM
    Chemotherapy; 2007; 53(5):360-9. PubMed ID: 17713326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.
    Gibson RJ; Stringer AM; Bowen JM; Logan RM; Yeoh AS; Burns J; Alvarez E; Keefe DM
    Cancer Biol Ther; 2007 Apr; 6(4):541-7. PubMed ID: 17457046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis.
    Bateman E; Weaver E; Klein G; Wignall A; Wozniak B; Plews E; Mayo B; White I; Keefe D
    Support Care Cancer; 2016 Jan; 24(1):377-385. PubMed ID: 26081596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice.
    Pedroso SHSP; Vieira AT; Bastos RW; Oliveira JS; Cartelle CT; Arantes RME; Soares PMG; Generoso SV; Cardoso VN; Teixeira MM; Nicoli JR; Martins FS
    Microbiology (Reading); 2015 Oct; 161(10):1950-1960. PubMed ID: 26224606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan.
    Arifa RDN; Paula TP; Madeira MFM; Lima RL; Garcia ZM; Ÿvila TV; Pinho V; Barcelos LS; Pinheiro MVB; Ladeira LO; Krambrock K; Teixeira MM; Souza DG
    Pharmacol Res; 2016 May; 107():102-110. PubMed ID: 26987941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation.
    Lima-Júnior RC; Figueiredo AA; Freitas HC; Melo ML; Wong DV; Leite CA; Medeiros RP; Marques-Neto RD; Vale ML; Brito GA; Oriá RB; Souza MH; Cunha FQ; Ribeiro RA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):931-42. PubMed ID: 22101361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis.
    Logan RM; Gibson RJ; Bowen JM; Stringer AM; Sonis ST; Keefe DM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):33-41. PubMed ID: 17703303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice.
    Lima-Júnior RC; Freitas HC; Wong DV; Wanderley CW; Nunes LG; Leite LL; Miranda SP; Souza MH; Brito GA; Magalhães PJ; Teixeira MM; Cunha FQ; Ribeiro RA
    Br J Pharmacol; 2014 May; 171(9):2335-50. PubMed ID: 24428790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile.
    Stringer AM; Gibson RJ; Bowen JM; Logan RM; Ashton K; Yeoh AS; Al-Dasooqi N; Keefe DM
    Int J Exp Pathol; 2009 Oct; 90(5):489-99. PubMed ID: 19765103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine.
    Kissow H; Viby NE; Hartmann B; Holst JJ; Timm M; Thim L; Poulsen SS
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):39-48. PubMed ID: 22729158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
    Melo ML; Brito GA; Soares RC; Carvalho SB; Silva JV; Soares PM; Vale ML; Souza MH; Cunha FQ; Ribeiro RA
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):775-84. PubMed ID: 17624531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties.
    Boeing T; de Souza P; Speca S; Somensi LB; Mariano LNB; Cury BJ; Ferreira Dos Anjos M; Quintão NLM; Dubuqoy L; Desreumax P; da Silva LM; de Andrade SF
    Br J Pharmacol; 2020 May; 177(10):2393-2408. PubMed ID: 31976547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Adaptor Protein Myd88 Is a Key Signaling Molecule in the Pathogenesis of Irinotecan-Induced Intestinal Mucositis.
    Wong DV; Lima-Júnior RC; Carvalho CB; Borges VF; Wanderley CW; Bem AX; Leite CA; Teixeira MA; Batista GL; Silva RL; Cunha TM; Brito GA; Almeida PR; Cunha FQ; Ribeiro RA
    PLoS One; 2015; 10(10):e0139985. PubMed ID: 26440613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
    Hamouda N; Sano T; Oikawa Y; Ozaki T; Shimakawa M; Matsumoto K; Amagase K; Higuchi K; Kato S
    Basic Clin Pharmacol Toxicol; 2017 Sep; 121(3):159-168. PubMed ID: 28374966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.